top of page

Welcome to Lixa

It's our mission to resolve recurring microbial infections and contaminations.

For anyone, anything and anywhere.
 

Together we move to a healthier future

Imagine a world without effective antimicrobials or antibiotics. 

 

Antimicrobial resistance (or AMR for short) happens when harmful microbes develop the ability to survive antimicrobials such as antibiotics.

​

Lixa reinvents anti-infection treatments by recognising that the development of new antibiotics is not solving the problem of AMR. 

 

We are developing an easily applicable, scalable and cost-effective technology platform, called NeoX™, that has the potential to restore the effectiveness of cheap, existing antimicrobials and biocides in the most resistant bacteria.

​

Breaking Antibiotic Resistance​

​

Bacteria develop resistance in two key ways:

1. As single bacteria, they evolve new "weapons" and "defences" that enable them to escape attack from antimicrobials.

​

2. Bacteria crowd together into colonies and create a gooey, protective barrier called a biofilm. Biofilm colonies can be up to 1000 times more resistant to antimicrobials.

 

Imagine being able to disperse the biofilm and convince bacteria to lay down their weapons. 

 

That’s the power of NeoX™.

​

AdobeStock_101448740.jpeg

Lixa is ultimately focused on developing world-wide and cross-sector scalable resistance breakers that restore the effectiveness of:

  • Any antibiotic, biocide or disinfectant

  • Against any resistant bacteria

  • In any infectious disease or bacterial problem

LIXA - October [03 10 23]-108.jpg

"AMR needs to be solved by combining multiple different technologies and expertise. 

 

Bacteria don’t care about borders.

A real AMR solution must be scalable across any country, species, or environment.

 

The Lixa technology is compatible with existing antimicrobials and is expected to be scalable regardless of economic environments and living standards.

 

Together we can make this world a better place.  

 

With Lixa, now we can."

Dr Maud Eijkenboom

CEO, Lixa 

​

bottom of page